Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and aiming to provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce’s internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. All applicants should be legally entitled to work for any employer in the U.S. For more information, please visit www.jouncetx.com.
View Top Employees from Jounce Therapeutics, Inc.Website | http://www.jouncetx.com |
Ticker | JNCE |
Revenue | $147 million |
Funding | $269.5 million |
Employees | 131 (131 on RocketReach) |
Founded | 2013 |
Address | 780 Memorial Drive, Cambridge, Massachusetts 02139, US |
Phone | (857) 259-3840 |
Fax | (617) 812-5345 |
Technologies |
JavaScript,
HTML,
PHP
+58 more
(view full list)
|
Industry | Biotechnology Research, Pharmaceuticals, Biotechnology, Cancer Immunotherapy, Healthcare, Science and Engineering, Immunology, Pharmaceutical, Oncology, Health Care, Antibody Development, Therapeutics |
Web Rank | 9 Million |
Keywords | Jounce Therapeutics, Tnbc By Rna But Not By Ihc, Jounce, Jounce Therapeutic Values, Jounce Therapeutics, Inc. Usa Hq Address |
Competitors | Adagene, Apellis Pharmaceuticals, Arcus Biosciences, Immatics, Replimune |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 541711 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541712 Companies, NAICS Code 541 Companies |
Looking for a particular Jounce Therapeutics, Inc. employee's phone or email?
The Jounce Therapeutics, Inc. annual revenue was $147 million in 2024.
Bill Goode is the Vice President of IT, Informatics, and Operations of Jounce Therapeutics, Inc..
131 people are employed at Jounce Therapeutics, Inc..
Jounce Therapeutics, Inc. is based in Cambridge, Massachusetts.
The NAICS codes for Jounce Therapeutics, Inc. are [54171, 541711, 54, 5417, 541712, 541].
The SIC codes for Jounce Therapeutics, Inc. are [873, 87].